0.01
+4900.00%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About T2 Biosystems
Its shares trade under the ticker TTOO. It has been listed since 7 August 2014. In the fiscal year to 31 December 2023, it reported revenue of $7.2m and a net loss of $50.1m. At that date it held total assets of $34.8m and shareholders' equity of −$28.0m.
T2 Biosystems, Inc. engages in the development of proprietary technology platform. The company is headquartered in Lexington, Massachusetts. The company went IPO on 2014-08-07. The firm's T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL). The firm's initial development efforts target sepsis, hemostasis and Lyme disease. T2MR is a miniaturized, magnetic resonance-based approach that measures how water molecules react in the presence of magnetic fields. Its platform detects a range of targets, including molecular targets, such as deoxyribonucleic acid (DNA), immunodiagnostics, such as proteins, and a range of hemostasis measurements. The firm offers T2Dx Instrument (T2Dx) and the T2Candida Panel.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 7 Aug 2014
- Employees
- 151
- Website
- t2biosystems.com ↗
Leadership
Pay as last reported
- Mr. Craig JalbertPresident, Chief Executive Officer, Corporate Treasurer, Corporate Secretary, Director, since 2025
- Dr. Roger SmithSenior Vice President of Science Research and Development
- Mr. Brett GiffinChief Commercial Officer
- Dr. Ninfa SaundersIndependent Director$50,000
- Mr. Philip TaylorInvestor Relations, since 2019
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 29
- Environment
- 33
- Social
- 21
- Governance
- 33
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- T2MR platform detects pathogens in whole blood with 1 CFU/mL sensitivity.
- T2Dx Instrument and T2Candida Panel target sepsis and fungal infections.
- T2 Biosystems employs 151 full-time staff in Lexington, Massachusetts.
Weaknesses
- T2 Biosystems has no product for hemostasis or Lyme disease detection yet.
- The company's initial focus on sepsis limits market expansion opportunities.
- T2 Biosystems' IPO was in 2014, which may limit recent funding.
Opportunities
- T2MR platform can expand to detect DNA and proteins in various samples.
- The firm can develop new panels for hemostasis and Lyme disease.
- T2 Biosystems can target global markets beyond the US.
Threats
- T2 Biosystems faces competition from established diagnostic firms in Health Care.
- The company's reliance on T2MR platform creates dependency risks.
- T2 Biosystems must navigate regulatory hurdles in the US and Europe.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.